NCT05610956 Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
| NCT ID | NCT05610956 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Tanta University |
| Condition | Ulcerative Colitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2023-01-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.
Eligibility Criteria
Inclusion Criteria: •Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis. Exclusion Criteria: * Other inflammatory bowel diseases (CD). * History of serious hypersensitivity to empagliflozin or any component of the formulation. * Patients on dialysis. * Severe renal impairment (eGFR \<20 ml/minute/1.73m2) . * Chronic urinary tract infection. * Chronic genital infection.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05610956 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05610956 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05610956 currently recruiting?
Yes, NCT05610956 is actively recruiting participants. Contact the research team at youmnahamdyeldeeb@gmail.com for enrollment information.
Where is the NCT05610956 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT05610956 clinical trial?
NCT05610956 is sponsored by Tanta University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.